Sean Chappin, MD
Addiction Medicine · Albany, NYNPI 1679740427
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 1,051 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 20.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $4,937, 2.6 times the $1,909 reported in 2019. Among addiction medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,051 payments — averaging $19.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Johnson & Johnson$2K
- Vanda Pharmaceuticals Inc.$2K
- Otsuka America Pharmaceutical, Inc.$1K
- Alkermes, Inc.$1K
- plus $7K from 22 others
What the payments were for
- Food & beverage$20,16299%
- Education$1611%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 222 | $4,212 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 130 | $2,360 |
| Johnson & Johnson(2 entities) | 73 | $2,002 |
| Vanda Pharmaceuticals Inc. | 89 | $1,893 |
| Otsuka America Pharmaceutical, Inc. | 73 | $1,369 |
| Alkermes, Inc. | 53 | $1,253 |
| Takeda Pharmaceuticals U.S.A., Inc. | 80 | $1,202 |
| Lundbeck LLC | 60 | $1,063 |
| Neurocrine Biosciences, Inc. | 45 | $840 |
| Axsome Therapeutics, Inc. | 49 | $835 |
| Teva Pharmaceuticals USA, Inc. | 40 | $785 |
| Corium, LLC | 37 | $746 |
| Sunovion Pharmaceuticals Inc. | 38 | $606 |
| E.r. Squibb & Sons, L.L.C. | 13 | $237 |
| Supernus Pharmaceuticals, Inc. | 12 | $219 |
| Orexo US, Inc. | 6 | $116 |
| Avanir Pharmaceuticals, Inc. | 7 | $99 |
| Shire North American Group Inc | 4 | $74 |
| Eisai Inc. | 3 | $69 |
| Collegium Pharmaceutical, Inc. | 3 | $68 |
| Almatica Pharma LLC | 3 | $58 |
| Idorsia Pharmaceuticals US Inc | 2 | $45 |
| Ironshore Pharmaceuticals Inc. | 2 | $45 |
| Merck | 3 | $44 |
| Biogen | 1 | $27 |
| Indivior Inc. | 1 | $22 |
| Bausch Health US, LLC | 1 | $19 |
| Alfasigma USA, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,324 in reported general payments places this provider in the 95th percentile of 125 addiction medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 30 | $76,281 |
| VraylarCariprazine Hcl | 25 | $39,401 |
| Risperdal ConstaRisperidone Microspheres | 20 | $20,864 |
| Aripiprazole | 138 | $8,919 |
| Lurasidone Hcl | 19 | $7,372 |
| Clomipramine Hcl | 13 | $6,453 |
| Bupropion XlBupropion Hcl | 166 | $4,612 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 53 | $4,469 |
| Atomoxetine Hcl | 31 | $2,286 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 96 | $2,168 |
| Duloxetine Hcl | 106 | $2,137 |
| Divalproex Sodium | 38 | $2,112 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 16 | $2,049 |
| Naltrexone Hcl | 21 | $1,707 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 20 | $1,521 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,369 | $76,28130 claims |
| AbbVieVraylar | $4,212 | $39,40125 claims |
| Johnson & JohnsonRisperdal Consta | $2,002 | $20,86420 claims |
| Almatica Pharma LLCSertraline Hcl | $58 | $1,140157 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 125 addiction medicine providers in New York.
Other addiction medicine in Albany
- Muhammed SaifAlbany$3K
- Angad MadanAlbany$450
- Edmond HakimiCalverton$125K
- Alain LitwinBronx$124K
- John MarianiNew York$38K
- Stefan KantrowitzNew York$33K
- Alejo ParelladaBrooklyn$22K
- Mohammad KabirTroy$15K
- Sonia LopezJamaica$14K
- Thomas KuettelWorcester$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.